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Introduction
In 2007, an employee of a manufacturing facility presented with severe obstructive lung 
disease. Surgical lung biopsy demonstrated hypersensitivity pneumonitis (HP), likely from 
workplace exposure to epoxy resin system (ERS) chemicals. The diagnosis was based both 
on her symptom and exposure history and on an abnormal blood lymphocyte proliferation 
test (LPT) to an epoxy resin hardener containing a proprietary amine and a polydiamine. 
Despite removal from exposure and aggressive pharmacologic treatment, she required lung 
transplantation.
Diverse industries ranging from electronics to construction use ERSs because of their 
physical properties and easy curing[1]. Market analysts predict over 3.03 million tons in 
annual sales of epoxy resin systems by 2017, potentially placing thousands of workers at 
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risk for exposure related health effects[2]. An ERS consists of several components: epoxy 
resins, plasticizers, adhesives, solvents, hardeners and blends of other resins. Health effects 
associated with ERSs vary depending on the particular components, many being pulmonary 
and dermatologic sensitizers and irritants[3, 4, 5]. The mechanisms for ERS health effects 
and risks for work-related lung disease from these exposures are poorly understood.
Similar to other forms of hypersensitivity pneumonitis, HP associated with ERS exposure 
likely occurs via a delayed-type hypersensitivity reaction[6]. This mechanism is important in 
the development of other granulomatous occupational lung diseases, such as chronic 
beryllium disease (CBD)[6]. CBD occurs via immunologic sensitization to beryllium, 
detected through in vitro testing of lymphocyte proliferation with beryllium salts[7]. Our 
sentinel patient developed abnormal lymphocyte proliferation to an epoxy thermoset 
hardener, suggesting sensitization as a mechanism leading to end-stage granulomatous lung 
disease. Findings in this patient suggested that an epoxy resin specific blood LPT might 
identify workers at risk for respiratory health effects associated with ERSs.
While much literature documents the epidemiology of occupational dermatitis due to epoxy 
resins, few systematic studies assessing occupational respiratory disease due to epoxy resins 
exist. Further, even though early identification of workers at risk for developing respiratory 
health effects from epoxies was targeted as an area for investigation in 1980, no strategies, 
such as identification of sensitized, but not symptomatic workers, currently exist[8]. This 
cohort study aimed not only to assess the prevalence of respiratory symptoms and 
spirometric abnormalities among ERS-exposed workers compared to demographically-
similar co-workers without ERS exposure, but to explore the utility of ERS lymphocyte 
proliferation testing (ERLPT) as a biomarker of exposure and immunologic sensitization in 
ERS workers compared to unexposed workers. If ERLPT positivity correlates with exposure 
status and ultimately with symptoms and spirometry outcomes, then ERLPT testing could 
serve as a surveillance tool to prevent occupational respiratory disease morbidity.
Materials and methods
Study subjects
We recruited study participants from a Colorado-based employer with over 1100 workers 
between August and October, 2010. Investigators reviewed job descriptions to determine the 
population working directly with ERS processes or entering areas where ERS are frequently 
used. The plant physician and safety officer verified the at-risk population of workers. We 
defined exposed workers as those who work directly in the epoxy area or within 30 feet and 
maintenance workers who routinely enter the epoxy area for purposes of cleaning. Exposed 
workers were grouped into two categories. Primary users of epoxy resins were considered 
higher exposed workers. We classified workers who entered epoxy areas for repairs, 
maintenance, janitorial duties, or who worked within 30 feet of the epoxy area lower 
exposed workers.
We recruited unexposed subjects from production areas where workers are not exposed to 
epoxy resins and from non-production areas in order to attempt one to one matching with 
exposed workers for age, race and gender. Pregnant workers were excluded.
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The study was approved by the National Jewish Health Institutional Review Board. 
Participants provided informed consent, and data were de-identified for analysis.
Methods
Questionnaire—We collected demographics and medical/occupational histories using a 
modified version of the ATS Respiratory Symptom Questionnaire[9]. Participants self-
completed questionnaires, and a trained interviewer reviewed and verified results.
Spirometry—Two NIOSH-certified technicians trained in ATS/ERS criteria for 
standardization of spirometry performed spirometry using two EasyOne Plus™ (ndd 
Medical Technologies, Inc., Zurich, Switzerland) spirometers. The quality grading function 
was activated. We excluded unacceptable spirometry (quality grades D or F) from analysis. 
A pulmonologist reviewed results to assure that they met ATS/ERS criteria for acceptability 
and repeatability[10]. Abnormal spirometry values included FEV1 or FVC values or 
FEV1/FVC ratios that fell below the lower limit of normal (LLN) based on Hankinson/
NHANES III predicted values[10,11].
Epoxy Resin Lymphocyte Proliferation Testing—We selected a panel of five ERS 
products for immunologic testing, shown in Table 1. We chose these products based on 
abnormal reactions in the ERLPTs performed in the sentinel case; on potential 
immunotoxicity of product components listed on Material Safety Data Sheets; and on 
reported volume of use at the worksite. The sentinel case showed abnormal reactions to the 
thermoset hardener, containing various amines. We performed ERLPT testing based upon 
the general technique used to perform LPT testing to beryllium sulfate[12].
Preparation of epoxy resins: A 1:10 vol/vol stock of the 5 different epoxy resin system 
components was prepared by adding 1 mL of the component to 9 mL complete RPMI-1640 
medium (RPMI-1640 (Irvine Scientific) supplemented with 10% human AB serum (Gemini 
Biologicals), 200mcg/ml L-glutamine (Fisher Scientific) and penicillin/streptomycin (Fisher 
Scientific). The five ERS components varied in viscosity: the triamine hardener, a clear 
liquid, went readily into solution; the trade secret epoxy, thermoset hardener, black epoxy 
and methacrylate adhesive were viscous, and care was taken to pipette approximately 1 mL 
into 9 mL complete media. Tubes were vortexed and placed at 37°C overnight to permit the 
ERS component to solubilize in complete media. The triamine hardener was readily soluble; 
the other four components remained essentially undissolved in media. Prior to use, the stock 
solutions were vortexed and working concentrations prepared by making serial 10-fold 
dilutions. The resins were tested at concentrations of 1:10, 1:100 and 1:1000.
Lymphoproliferation assay: Venous blood (30 mL) was collected in 10 mL sodium 
heparin tubes from each participant. Mononuclear cells were isolated by Histopaques-1077 
(Sigma) density centrifugation, washed in phosphate buffered saline, and re-suspended in 
complete medium. Mononuclear cells were cultured in triplicate at 2.5 × 105 cells/well in 
round-bottomed, 96-well microtiter plates (Fisher Scientific) in the presence of complete 
medium and dilutions of each of the 5 ERS components for 6 days. As positive controls, 
cells were incubated with phytohemagglutinin (5 mcg/mL) for 3 days or with Candida 
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albicans (20 mcg/mL) for 6 days. At the end of the incubation period, cells were pulsed with 
tritiated thymidine (Perkin Elmer), 1 mCi/well, and incubated for a further 6 hours before 
harvesting and quantification for 3H incorporation by liquid scintillation. Proliferation was 
assessed by the degree of cellular incorporation of tritiated thymidine. Results were 
expressed as stimulation index (SI), the mean response observed at any concentration of 
component divided by the mean response of the unstimulated cells grown under the same 
conditions in the absence of the potential sensitizer.
SIs were calculated for three concentrations each of five epoxy resin products. An abnormal 
test result was determined based on an SI exceeding the product-specific cut-off point. Each 
cut-off point was determined by taking the mean peak SI for unexposed workers in this 
population and adding two standard deviations. Standard deviations and coefficients of 
variation (CV) were calculated for all conditions. If a calculated CV was greater than 0.5, 
the value was excluded from analysis.
Analysis
We used Intercooled STATA 11.2 (Stata Corp, College Station, Texas) for all analyses. In 
bivariate analysis, we used several tests: The chi-square test was used to determine if 
exposure groups differed in demographic variables or reported symptoms. Fisher's exact 
tests were used to compare categorical data (such as presence of comorbidities) for small 
numbers of responses (less than 20).
Normality was assessed using the Shapiro-Wilkes test. We assessed differences in means 
between the three exposure groups using analysis of variance when outcome data were 
normally distributed (i.e., LPT peak SIs for methacrylate adhesive, black epoxy, thermoset 
hardener), and the Kruskal-Wallis test when continuous outcome data were not normally 
distributed (i.e., LPT peak SIs for trade secret epoxy & triamine hardener).
In multivariate analysis, we used linear regression to examine associations between 
continuous outcomes (FEV1 % Predicted, FVC % Predicted, and FEV1/FVC ratio) and 
exposure categories while adjusting for factors known to be associated with pulmonary 
function, such as age (for FEV1/FVC), smoking status (current smokers versus former or 
nonsmoker), and socioeconomic status. We used education status (college versus no college) 
as a proxy for socioeconomic status. Other factors, such as years worked for the company, 
were investigated and retained if they were significant predictors in the model. Due to the 
small number of affirmative responses in many outcomes, we used exact logistic regression 
to examine associations between dichotomous outcomes (such as symptoms or presence of 
FVC or FEV1 < LLN) and exposure categories. Smoking status was assessed as current 
smoker versus former or non-smoker, due to the necessity of use of a dichotomous variable 
with exact logistic regression. We were unable to adjust for the continuous variable of tenure 
in exact logistic regression models. In order to account for age in the symptom exact logistic 
regression model, we categorized age into two groups: younger than 50, and 50 and above. 
Age 50 was selected due to distribution of the data and biologically plausible expected 
variations in symptoms starting at age 50. Age is already accounted-for in the exact logistic 
regression evaluation for outcomes of FVC or FEV1 < LLN, as part of the expected values 
for LLN determination.
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We identified 47 workers potentially exposed to epoxy resins from job description lists. All 
eligible workers were contacted and offered participation in the medical screening program. 
Of the nine workers who declined participation, none were primary users of epoxy resins. 
Overall, 81% of eligible workers participated in this voluntary program. Table 2 describes 
characteristics of 70 workers participating in the medical screening. Unexposed workers did 
not differ from either lower or higher exposed workers by gender, race, age, hours worked 
or education level. Exposed workers were more likely to currently smoke. There was also a 
statistically significant difference in employment tenure at the company, with the lower 
exposed group having the longest tenure.
Medical History and Symptoms
Table 2 also describes pertinent medical co-morbidities in this population. Higher exposed 
workers more often reported heart disease than lower or unexposed workers (p=0.025), 
though this group was also slightly older and included more current smokers. Groups did not 
differ for any respiratory diseases; however, there was a high prevalence of allergies for all 
three, ranging from 48-56%. A significantly greater percentage of higher exposed workers 
used inhaled medications (18%) compared to unexposed (3%).
Table 3 shows Odds Ratios for symptoms according to exposure groups. Because the 
presence of current smoking was low overall, and because only one subject in the unexposed 
group was a current smoker (See Table 2), we analyzed symptom reporting among the 
current non-smokers only, rather than attempting to adjust for smoking. We did adjust for 
age. Higher exposed workers were significantly more likely to report wheezing (OR 5.91, 
[1.07-41.42], p=0.041) than unexposed workers. The lower exposed workers were more 
likely to report achiness than unexposed workers (OR 10.86, [1.05-∞], p=0.045). Although 
not statistically significant, we observed a pattern of higher exposed workers more 
frequently reporting cough, shortness of breath, chest tightness, and producing phlegm, 
compared to lower exposed and unexposed workers.
Spirometry
Of 70 workers who performed spirometry, 67 (96%) achieved results meeting ATS/ERS 
criteria for acceptability and repeatability and were included in analysis. Among 16 higher 
exposed workers, five (31.3%) had an FEV1 < LLN compared to two of 20 (10%) lower 
exposed workers and one of 31 (3.2%) unexposed workers. Similarly, four of 16 (25.0%) 
higher exposed workers had an FVC < LLN compared to three of 20 (15.0%) lower exposed 
workers and three of 31 (9.7%) unexposed workers. Among the 10 workers with FVC below 
the LLN, seven had body mass indices above 30.
We found no statistically significant differences between exposure group and abnormal 
spirometry (Table 4). We did, however, observe a similar pattern to that seen with 
respiratory symptoms: higher exposed workers had a greater frequency of abnormal 
spirometry (FEV1 most notably) than the lower or unexposed groups after adjusting for 
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smoking. We found no significant differences for decreased FEV1/FVC ratio < LLN among 
exposure groups (p=0.537) in bivariate analysis. For all workers with spirometric values 
below the LLN, clinical follow-up was recommended.
Mean values of FVC percent predicted, FEV1 percent predicted and FEV1/FVC all fell 
within clinically normal ranges (Figure 1). Mean FEV1 percent predicted for unexposed 
workers was 98.0 ±12.0, lower exposed workers was 94.8 ±10.9, and higher exposed 
workers was 90.6 ± 17.3. Similarly, FVC percent predicted for unexposed workers was 96.5 
± 12.3, lower exposed workers was 95.9 ±9.9, and higher exposed workers was 91.0 ± 15.5. 
FEV1/FVC ratio for the unexposed was 81.2 ± 4.4, lower exposed was 79.4 ± 5.4, and 
higher exposed was 77.5 ± 6.9.
Table 5 shows that, after adjustment for smoking, education level and age (for FEV1/FVC), 
there were no significant differences in mean FVC or FEV1 percent predicted or FEV1/FVC 
ratio among the three groups. Despite finding normal mean spirometry values, there was a 
pattern for all parameters, as seen in Figure 1 and in the regression coefficients by exposure 
categories, showing decreasing lung function associated with increasing exposure. While 
higher exposed workers were slightly older (mean age 50.4 years) than the unexposed group 
(mean age 42.9 yrs), the percent predicted values in the higher exposed workers showed a 
pattern of lower FEV1 (p=0.172) and FVC (p=0.176) compared to unexposed workers, even 
accounting for age, education and smoking. We also examined spirometry endpoints using 
duration of employment to assess for any additional exposure effect. Duration of 
employment was not a significant predictor in the linear regression models and was 
therefore not included in the final models.
Lymphocyte Proliferation Testing
Few workers had LPT stimulation indices exceeding the statistical cut-off points for any 
ERS products. For the trade secret epoxy, only two of the higher and lower exposed workers 
and no unexposed workers demonstrated abnormal LPTs. For the triamine hardener, only 
one exposed worker and one unexposed worker had abnormal results. Similarly, only one 
unexposed and no exposed workers had abnormal LPTs to the black epoxy. All workers had 
normal responses to the methacrylate adhesive and the thermoset hardener. There were no 
significant differences in proportion with abnormal LPTs between exposure groups.
Discussion
In this population of 70 workers, we found greater frequencies of reported respiratory 
symptoms, use of inhaled medications, and abnormal FEV1 and FVC results in higher 
exposed workers compared to unexposed workers. This remained statistically significant for 
symptoms of cough and wheeze when adjusted for smoking. Although not statistically 
significant, the pattern remained consistent across other respiratory outcomes after smoking 
adjustment. While mean FEV1 and FVC percent predicted values and FEV1/FVC ratios 
were within normal ranges, we saw an exposure-response gradient in both FEV1 and FVC 
percent predicted for unexposed, lower exposed and higher exposed worker populations, 
suggesting even in this cross-sectional study that those with higher ERS exposure may be at 
risk for occupational lung disease. Although we were hopeful to demonstrate a biomarker 
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that could identify workers at risk to develop occupational illness prior to onset of disease, 
epoxy resin LPT did not consistently predict exposure status in this worker population.
ERS chemicals are well-known causes of occupational asthma, particularly the acid 
anhydrides and aliphatic polyamines[1]. The mechanisms for ERS-related occupational 
asthma remain uncertain, with debate as to whether epoxy monomers can cause immune-
mediated asthma[13], or whether activating agents like anhydrides and amines impart such 
risk exclusively. Our findings suggest that ERS-exposed workers are at risk for airflow 
obstruction and respiratory symptoms. An on-going longitudinal medical surveillance 
program for these workers will include spirometry and symptom questionnaires, with 
follow-up and referral of workers in whom occupational illness is suspected.
Epoxy resin system components also cause allergic contact dermatitis. Recently, thirteen 
epoxy resins were tested for skin-sensitization potential using a local lymph node assay, all 
with abnormal results[14]. Dermal absorption is an important route of exposure, conferring 
risk for some occupational lung diseases including those associated with beryllium and 
isocyanates[15]. Though our study focused on respiratory health effects, the questionnaire 
included queries on skin symptoms. Eight workers reported regularly experiencing skin rash, 
mainly on areas of skin that came in contact with chemicals and the majority reportedly 
occurring in relation to work. Future investigations of ERS-related lung disease should focus 
on elucidating skin symptoms and dermal exposure in at-risk workers.
The impetus for this study followed diagnosis of an ERS production worker with HP based 
on biopsy findings of poorly-formed granulomas and severe constrictive bronchiolitis, 
ultimately requiring lung transplantation for end-stage obstructive lung disease. This sentinel 
case demonstrated a high LPT SI (35.5) to a hardener containing a mono- and polydiamine 
and a modestly elevated SI (3.7) to an epoxy resin containing a bisphenol A epoxy resin. 
However, in our study population, we did not find that LPT was a useful biomarker in 
identifying exposed or sensitized workers.
Lymphocyte proliferation tests have been investigated clinically and experimentally in the 
diagnosis of hypersensitivity and drug-induced pneumonitis. LPTs have been tested to 
isocyanates[16,17], antibiotics[18], methotrexate[19], Trichosporon asahi[20], smut 
spores[21], pigeon serum, and feather antigens [22,23]. The ERS chemicals tested in this 
study were heterogeneous and included amines, epoxy resins, and methacrylates. In 
industrial applications, these products interact to accomplish their desired effects of bonding 
and adherence. In our LPT testing, each product was tested in isolation. We do not know if 
testing the component mixture would elicit different results, or even if such a process would 
be feasible in an in vitro cell-based testing system. Moreover, LPT may be useful primarily 
in those with granulomatous lung diseases such as HP, with less relevance as a biomarker in 
other more common ERS-related occupational diseases such as asthma.
There are several limitations to our study. This study had a small study population due to the 
limited nature of exposure at the facility, where only 47 out of 1100 potentially faced 
exposure. While the small study population did influence power to detect statistically 
significant differences in pulmonary function, the exposure-response patterns seen for the 
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symptom and pulmonary function outcomes are consistent and potentially concerning. These 
exposure-response patterns remained consistent after adjusting for key factors known to be 
associated with pulmonary function, such as smoking. Furthermore, while reporting bias 
could lead to differences in symptom reporting, the spirometry data supports an objective 
association between pulmonary function change and exposure.
In the absence of concurrent workplace exposure sampling, we focused more on exposure 
assessment as predicted by the job location and description with review by the plant Safety 
Officer and OEM Physician. Exposure sampling by the company following identification of 
the sentinel case showed that most ERS chemical levels were non-detectable or extremely 
low. Since the sentinel case was recognized, local exhaust ventilation and other engineering 
controls were improved, suggesting that current workplace exposures may be different from 
historical exposures. Misclassification in the unexposed group based on past occupational or 
low-level recreational exposures is possible; however, random misclassification should bias 
results to the null, and we still saw significant effects of exposure on cough, wheeze and use 
of inhaled medications.
In this exploratory research in the use of epoxy resin LPT to assess sensitization, the 
concentrations of epoxy materials used in the LPTs were determined by preliminary toxicity 
studies. A well-known challenge of LPT performance is determining the optimal 
concentration of antigen that is adequate to allow a proliferative response without being so 
high as to induce cytotoxicity. Further work is needed to explore the utility of ERS LPT, 
including identification of optimal antigen concentrations, feasibility of testing chemical 
mixtures, and culture conditions that might permit more successful antigen presentation with 
poorly soluble materials.
In summary, in this population where most chemical exposures appear to be well controlled, 
we observed a consistent pattern of workers in the higher exposed jobs more frequently 
reporting respiratory symptoms and showing decreased lung function compared to 
unexposed workers. Targeted medical surveillance along with more in-depth investigation of 
epoxy resin system chemical exposures and immunotoxicity, combined with improved 
worker hazard communication, will provide opportunities for prevention of a spectrum of 
potentially disabling occupational diseases.
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Figure 1. Exposure-response in spirometry values for Epoxy Workers
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Table 1
Selected Epoxy Resin System components chosen for Lymphocyte Proliferation Testing 
(LPT)
Product type Components listed on MSDS
trade secret epoxy Proprietary Epoxy Resin, unknown %
Proprietary Alkyl Glycidyl Ether, unknown %
Microcrystalline silica, 51-60%
triamine hardener Polyoxypropylenetriamine, 81-90%
Alkyl Amine Mixture, unknown %





1,3-Butylene glycol dimethacrylate, 1-5%
black epoxy Proprietary Epoxy Resin, ≤50%
Crystalline silica, ≤50%
Proprietary Epoxy Resin, ≤5%
Carbon Black, ≤1%
thermoset hardener Crystalline silica, ≤50%
Proprietary Polydiamine, ≤15%
Proprietary Amine Compound, ≤15%
4-Nonyl phenol, ≤10%
Components in italics most likely immunologically active.
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Table 2
Characteristics & Medical History of 70 Workers at an Industrial Manufacturing Facility




Age (years) 50.40 (14.12) 41.07 (12.08) 42.86 (13.51) 0.081
Tenure at company (years) 6.59 (3.81) 10.36 (9.97) 4.19 (4.99) 0.007
Hours worked/week 44.65 (5.28) 41.90 (2.84) 42.84 (7.41) 0.357
n (%)
Gender
 Male 11 (64.71) 16 (76.19) 22 (68.75) 0.728
 Female 6 (35.29) 5 (23.81) 10 (31.25)
Race
 White 16 (94.12) 18 (85.71) 28 (87.50) 0.796
 Latino 1 (5.88) 3 (14.29) 4 (12.50)
Current Smoking Status
 Current smoker 6 (35.29) 5 (23.81) 1 (3.13) 0.005
 Non-smoker 11 (64.71) 16 (76.19) 31 (96.88)
Education Level
 High School only 9 (52.94) 9 (42.86) 7 (21.88) 0.069
 College + 8 (47.06) 12 (57.14) 25 (78.13)
History of:
 • Allergies 9 (52.94) 10 (47.62) 18 (56.25) 0.827
 • Asthma 3 (17.65) 4 (19.05) 2 (6.25) 0.303
 • Chronic bronchitis, mphysema, 
COPD
2 (11.76) 2 (9.52) 0 (0.00) 0.104
 • Sinus trouble 3 (17.65) 5 (23.81) 8 (25.00) 0.874
 • Hay fever 3 (17.65) 5 (23.81) 9 (28.13) 0.726
 • Pneumonia 3 (17.65) 4 (19.05) 5 (15.63) 0.999
 • Heart Disease 3 (17.65) 1 (4.76) 0 (0.00) 0.025
 • Tuberculosis 0 (0.00) 1 (4.76) 0 (0.00) 0.543
 • Other Lung Disease 0 (0.00) 1 (4.76) 1 (3.13) 0.999
 • Currently taking medications 10 (58.82) 7 (33.33) 18 (56.25) 0.186
  • Taking breathing medications** 3 (30.00) 3 (42.86) 1 (5.56) 0.047
  • Taking corticosteroids 0 0 0
*
No one reported lung surgery, sarcoidosis, hypersensitivity pneumonitis, or a previous chest injury.
**
Among 35 workers reported currently taking medications.
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